EBITDA Margin % is calculated as EBITDA divided by its Revenue. TransMedics Group's EBITDA for the
three
months ended in Mar. 2026 was €23.8 Mil. TransMedics Group's Revenue for the
three
months ended in Mar. 2026 was €150.5 Mil. Therefore, TransMedics Group's EBITDA margin for the quarter that ended in Mar. 2026 was 15.82%.
TransMedics Group (HAM:8T8) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
TransMedics Group EBITDA Margin % Related Terms
TransMedics Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for TransMedics Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:8T8 vs AXGN, BFLY, ESTA: EBITDA Margin % Comparison
For the Medical Devices subindustry, TransMedics Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransMedics Group EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where TransMedics Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransMedics Group (HAM:8T8) has a EBITDA Margin % of 15.82% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TransMedics Group and its competitors. According to the industry distribution chart, TransMedics Group ranks #171 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 21%.
Is TransMedics Group's EBITDA Margin % too high?
TransMedics Group's current EBITDA Margin % is 15.82%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.39. TransMedics Group's value of 15.82% is 114.2% above this industry median. Based on the distribution chart, TransMedics Group ranks #171 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, TransMedics Group has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's EBITDA Margin % compare to AXGN and BFLY?
According to the Medical Devices & Instruments industry distribution chart, TransMedics Group ranks #171 out of 816 companies for EBITDA Margin %. This places TransMedics Group in the top 21% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.39. TransMedics Group's value of 15.82% is 114.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.39, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransMedics Group's current EBITDA Margin % of 15.82% is 114.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TransMedics Group and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransMedics Group's current EBITDA Margin % is 15.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
TransMedics Group (HAM:8T8) has a current EBITDA Margin % of 15.82%. The stock's GF Value™ is €162.08, compared to a current price of €60.02 — trading 63% below its estimated fair value. The current EBITDA Margin % is 15.82% and 114.2% above the Medical Devices & Instruments industry median of 7.39. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TransMedics Group (HAM:8T8), the current EBITDA Margin % is 15.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TransMedics Group (HAM:8T8) Overvalued in 2026?
Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued.
The current stock price of €60.02 is trading 63% below its estimated GF Value™ of €162.08.
Key valuation signals for HAM:8T8:
EBITDA Margin %: 15.82%
GF Value™: €162.08 vs. price of €60.02 (63% below fair value)
Industry Position: 114.2% above the Medical Devices & Instruments median (#171 of 816)
No single metric tells the full story. See the HAM:8T8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score
Get the complete analysis for HAM:8T8
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:8T8 has been successfully added to your 
